Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial

Annals of Oncology

Volumn 25, Issue 2, 2014, Pages 429-434

  Sternberg, Cora N ^a   de Bono, J S ^b   Chi, K N ^c   Fizazi, K ^d   Mulders, P ^e   Cerbone, L ^a   Hirmand, M ^f   Forer, D ^f   Scher, H I ^g  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Medivation Inc   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

AFFIRM trial; Elderly patients; Enzalutamide; Metastatic castration resistant prostate cancer

Indexed keywords

ABIRATERONE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ANDROGEN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN;

AGE; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; GERIATRICS; HOT FLUSH; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MULTICENTER STUDY (TOPIC); NAUSEA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; VOMITING; ANALOGS AND DERIVATIVES; BONE NEOPLASMS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIAL; SECONDARY; TREATMENT OUTCOME;

AGED; ANDROGEN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PHENYLTHIOHYDANTOIN; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME;

EID: 84893349290     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt571     Document Type: Article

References (18)

1. Droz JP, Chaladaj A. Management of metastatic prostate cancer: the crucial role of geriatric assessment. BJU Int 2008; 101(Suppl 2): 23-29.
2. de Camargo Cancela M, Comber H, Sharp L. Age remains the major predictor of curative treatment non-receipt for localised prostate cancer: a population-based study. Br J Cancer 2013; 109: 272-279.
3. Scosyrev E, Messing EM, Mohile S et al. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer 2012; 118: 3062-3070.
4. Italiano A, Ortholan C, Oudard S et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009; 55: 1368-1375.
5. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
6. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
7. Fizazi K, Scher HI, Molina A et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983-992.
8. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223.
9. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197.
10. Mulders PF, Molina A, Marberger M et al. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castrationresistant prostate cancer after docetaxel-based chemotherapy. Eur Urol 2013 September 20 [epub ahead of print], doi: 10.1016/j.eururo.2013.09.005.
11. Midzak AS, Chen H, Papadopoulos V et al. Leydig cell aging and the mechanisms of reduced testosterone synthesis. Mol Cell Endocrinol 2009; 299: 23-31.
12. Dai B, Qu Y, Kong Y et al. Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer. BJU Int 2012; 110(11 Pt B): E667-E672.
13. García-Cruz E, Piqueras M, Huguet J et al. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment. BJU Int 2012; 110(11 Pt B): E541-E546.
14. United States National Institutes of Health. ClinicalTrials.gov. Enzalutamide trials. A safety and efficacy study of oral MDV3100 in chemotherapy-naive patients with progressive metastatic prostate cancer (PREVAIL). http://www.clinicaltrials.gov/ct2/ show/NCT01212991 (3 March 2013, date last accessed).
15. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-148.
16. Rathkopf DE, Smith MR, De Bono JS et al. (2013) Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castrationresistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302). In Proceedings from the American Society of Clinical Oncology Annual Meeting. 31 May-4 June 2013, Chicago, IL, USA. (abstr 5009).
17. United States National Institutes of Health. ClinicalTrials.gov. Orteronel trials. Study comparing orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. http://clinicaltrials.gov/show/ NCT01193244 (12 May 2013, date last accessed).
18. United States National Institutes of Health. ClinicalTrials.gov. Tasquinimod trials. Study comparing orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. http://www.clinicaltrials.gov/ct2/ show/NCT01234311 (12 May 2013, date last accessed).